

## 2 The ongoing COVID-19 epidemic in Minas Gerais, Brazil: insights from epidemiological data and SARS-CoV-2 whole genome sequencing.

4 Joilson Xavier<sup>1¶</sup>, Marta Giovanetti<sup>1,2¶</sup>, Talita Adelino<sup>1,3¶</sup>, Vagner Fonseca<sup>1,4,6¶</sup>, Alana Vitor Barbosa  
da Costa<sup>3</sup>, Adriana Aparecida Ribeiro<sup>3</sup>, Katlin Nascimento Felicio<sup>3</sup>, Clara Guerra Duarte<sup>3</sup>, Marcos  
6 Vinicius Ferreira Silva<sup>3</sup>, Álvaro Salgado<sup>1</sup>, Mauricio Teixeira Lima<sup>1</sup>, Ronaldo de Jesus<sup>1,6</sup>, Allison  
Fabri<sup>2</sup>, Cristiane Franco Soares Zoboli<sup>3</sup>, Thales Gutemberg Souza Santos<sup>3</sup>, Felipe Iani<sup>1,3</sup>, Ana Maria  
8 Bispo de Filippis<sup>2</sup>, Marilda Agudo Mendonça Teixeira de Siqueira<sup>5</sup>, André Luiz de Abreu<sup>6</sup>, Vasco  
de Azevedo<sup>1</sup>, Dario Brock Ramalho<sup>7</sup>, Carlos F. Campelo de Albuquerque<sup>8</sup>; Tulio de Oliveira<sup>4</sup>, Ed-  
10 ward C. Holmes<sup>9</sup>, José Lourenço<sup>10¶\*</sup>, Luiz Carlos Junior Alcantara<sup>1,2¶\*</sup>, Marluce Aparecida As-  
sunção Oliveira<sup>3¶\*</sup>.

12

<sup>1</sup>Laboratório de Genética Celular e Molecular, ICB, Universidade Federal de Minas Gerais, Belo  
14 Horizonte, Minas Gerais, Brazil; <sup>2</sup>Laboratório de Flavivírus, Instituto Oswaldo Cruz Fiocruz, Rio  
de Janeiro, Brazil; <sup>3</sup>Laboratório Central de Saúde Pública, Fundação Ezequiel Dias, Belo Horizonte,  
16 Brazil; <sup>4</sup>KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), College of Health  
Sciences, University of KwaZuluNatal, Durban 4001, South Africa; <sup>5</sup>Laboratório de Vírus Res-  
18 piratórios e Sarampo, Instituto Oswaldo Cruz Fiocruz, Rio de Janeiro, Brazil; <sup>6</sup>Coordenação Geral  
dos Laboratórios de Saúde Pública/Secretaria de Vigilância em Saúde, Ministério da Saúde,  
20 (CGLAB/SVS-MS) Brasília, Distrito Federal, Brazil; <sup>7</sup>Secretaria de Estado de Saúde de Minas Ge-  
rais; Belo Horizonte, Brazil; <sup>8</sup>Organização Pan-Americana da Saúde/Organização Mundial da  
22 Saúde, Brasília-DF, Brazil; <sup>9</sup>Marie Bashir Institute for Infectious Diseases and Biosecurity, School  
of Life and Environmental Sciences and School of Medical Sciences, University of Sydney, Syd-  
24 ney, NSW, Australia; <sup>10</sup>Department of Zoology, University of Oxford, Oxford OX1 3PS, UK.

26

¶These authors contributed equally

28

30 \* Corresponding authors: [luiz.alcantara@ioc.fiocruz.br](mailto:luiz.alcantara@ioc.fiocruz.br) (LCJA); [jose.lourenco@zoo.ox.ac.uk](mailto:jose.lourenco@zoo.ox.ac.uk) (LJ);

[marluce.oliveira@funed.mg.gov.br](mailto:marluce.oliveira@funed.mg.gov.br) (MAAO)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 32 **Abstract**

The recent emergence of a previously unknown coronavirus (SARS-CoV-2), first confirmed in the  
34 city of Wuhan in China in December 2019, has caused serious public health and economic issues  
due to its rapid dissemination worldwide. Although 61,888 confirmed cases had been reported in  
36 Brazil by 28 April 2020, little was known about the SARS-CoV-2 epidemic in the country. To better  
understand the recent epidemic in the second most populous state in southeast Brazil (Minas Gerais,  
38 MG), we looked at existing epidemiological data from 3 states and sequenced 40 complete genomes  
from MG cases using Nanopore. We found evidence of multiple independent introductions from  
40 outside MG, both from genome analyses and the overly dispersed distribution of reported cases and  
deaths. Epidemiological estimates of the reproductive number using different data sources and  
42 theoretical assumptions all suggest a reduction in transmission potential since the first reported case,  
but potential for sustained transmission in the near future. The estimated date of introduction in  
44 Brazil was consistent with epidemiological data from the first case of a returning-traveler from  
Lombardy, Italy. These findings highlight the unique reality of MG's epidemic and reinforce the  
46 need for real-time and continued genomic surveillance strategies as a way of understanding and  
therefore preparing against the epidemic spread of emerging viral pathogens.

48

**Keywords:** SARS-CoV-2; genomic surveillance; southeast Brazil; pandemic; sequencing

50

52

54

## 56 **Introduction**

The World Health Organization (WHO) office in China was informed about a cluster of new cases of pneumonia of unknown etiology in the City of Wuhan (Hubei province), in late December 2019 [1]. Shortly afterwards, a new type of coronavirus, now termed SARS-CoV-2, was isolated and identified by Chinese authorities, with its genetic sequence shared with the international community on 10 January 2020 [2–5]. Phylogenetic analysis revealed that SARS-CoV-2 was similar to other (pandemic) betacoronaviruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) [4,5]; revealing also its phylogenetic relationship to other coronaviruses isolated from bats and Malayan pangolins (*Manis javanica*), indicating a likely zoonotic origin [2,5–7].

To date, more than 3.5 million cases of the disease caused by SARS-CoV-2, termed COVID-19, have been reported around the world [8,9]. On 11 March 2020, the WHO declared the COVID-19 a pandemic, prompting a dramatic increase in international concern and response [10]. On 26 February 2020, the first confirmed case of COVID-19 was reported in São Paulo (SP) state, Brazil [11]. Two months later (28 April 2020), 61,888 cases and 4,205 deaths attributed to COVID-19 had been reported in Brazil [12]. Meanwhile, preliminary phylogenetic analysis using the first two SARS-CoV-2 complete genomes isolated in São Paulo from travelers returning from Italy, revealed two independent introductions into the country, relative to the analyzed dataset available at that time [13].

The state of Minas Gerais (MG) is the second largest Brazilian state in terms of population size, estimated at approximately 21 million people, and is located near the state of São Paulo [14]. Due to its large population size and its well-connected and active neighboring states such as São Paulo and Rio de Janeiro, the state of MG is likely to be highly affected by the COVID-19 pandemic.

Genetic analyses and surveillance allow the characterization of circulating viral lineages, the inference of introduction events and the reconstruction of transmission patterns [15]. Together with

epidemiological data, they are powerful tools to assist public health initiatives and preparedness. In  
82 this study, we present a summary of epidemiological data and the generation and analysis of 40 new  
SARS-CoV-2 genome sequences isolated from clinical samples of confirmed cases from MG, with  
84 the aim of providing a preliminary epidemiological overview of the circulation and introduction  
events of the virus in that state.

86

## Results/Discussion

88 After the WHO declared the outbreak of SARS-CoV-2 a Public Health Emergency of International  
Concern (PHEIC) on 30 January 2020, the Brazilian government declared a Public Health  
90 Emergency of National Importance on 3 February 2020, enabling the introduction of measures to  
prevent and control spread [16]. Twenty-three days later, the first confirmed case in Brazil was  
92 reported in the city of São Paulo, related to a traveler returning from Lombardy, Italy (Fig 1) [11].

By the 28 April 2020, more than 61,888 COVID-19 cases were confirmed in Brazil, 1,578 of which  
94 were from MG (Fig 2A) [17]. Over this period, MG registered 71 COVID-19-related deaths, and  
the capital city Belo Horizonte, with an estimated population of 2.5 million people, had reported  
96 555 cases [17,18]. Fig 2A shows MG's epidemic (reported cases) curve compared to the curves of  
two other neighboring states, São Paulo (SP) and Rio de Janeiro (RJ).

98 Without access to the total number of tests in time and in each state, we calculated the case fatality  
ratio (CFR) for MG, SP and RJ as the crude ratio between reported deaths and cases [19]. The CFR  
100 was found to increase with time in all states (S2 Fig), with means from date of first reported case up  
to the 28 April in each state at 2.67% for MG, 5.39% for RJ and 6.0% for SP. For SP and RJ, the  
102 CFR was consistently higher than reported elsewhere; for example at 2.6% (95% CI 0.89-6.7) for  
the Diamond Princess cruise ship [20], and 3.67% (95% CI 3.56-3.80) and 1.2% (95% CI 0.3-2.7)  
104 and 1.4% (95% CI 0.9-2.1) for Chinese regions [20–22].

106 We used the mortality time series (MTS) from MG, SP and RJ to project the cumulative number of  
infections, making two main simplifying assumptions: first, that the infection fatality ratio (IFR) of  
108 SARS-CoV-2 would be similar in the Brazilian states to that reported elsewhere; and second, that  
the number of cumulative deaths in each state were well reported. We considered the IFR estimated  
110 by Verity and colleagues (0.66%, CI 95% 0.39-1.33% [21]), for its general use in the modelling  
literature [23]. The cumulative number of infections in time is taken to be  $I(t) = \frac{D(t)}{\frac{IFR}{100}}$ , where  $D(t)$   
112 is the cumulative number of deaths. From  $I(t)$  we further obtain the observation rate  $\theta$  of reported  
cases from  $\theta(t) = \frac{c(t)}{I(t)}$  where  $c(t)$  is the number of reported cases in time. We found the  
114 observation rate to have decreased in time for all states - a likely outcome of successful tracing and  
testing only in the beginning, but with epidemic growth superseding tracing and testing efforts as  
116 the epidemic progressed (S1 Fig). By 28 April 2020, the last time point analyzed, RJ and SP had  
similar observation rates at 7.6% and 7.74% (respectively), while MG, where the epidemic started  
118 later, the observation rate was 15.3% (1 case in 7 infections).

To compare transmission potential, we used reported cases (CTS) and mortality time series (MTS)  
120 from MG, SP and RJ states to estimate the (effective) reproduction number  $R$ . For this, we  
performed maximum likelihood estimation of the (CTS and MTS) epidemic growth  $r$  using a  
122 phenomenological model, and two theoretical formulations on how  $r$  relates to  $R$  - one based on the  
SEIR epidemiological framework by Wallinga and colleagues [24], and another on the distribution  
124 of the serial interval [23] (see Supplementary Material for details).  $R$  was found to decrease in time  
since first reported case for all states (S5 and S10 Figs). When considering the entire period from  
126 first reported case to the 28 April, estimation methods gave similar  $R$  results per state (S6 and S11  
Figs). For example, when using the CTS and serial interval formulation,  $R$  was 1.91 (CI 95% 1.2-  
128 3.1) for SP, 1.88 (CI 95% 1.27-2.8) for RJ and 1.82 (CI 95% 1.2-3.25) for MG.

130 When using geographic information from reported cases in each state (Fig 2C and S13-14 Figs), we  
found that cases were generally very dispersed in MG and more centralized around capital cities in  
132 RJ and SP. In MG, reported cases were on average ~103 km away (CI 95% 1.39-488) from the  
capital Belo Horizonte, while in SP they were ~0.05 km away from the city of São Paulo (CI 95%  
134 0.05-269), and in RJ ~1.45 km away from the city of Rio de Janeiro (CI 95% 1.4-130). Similar  
patterns were found for reported deaths (Fig 2B and S15-16 Figs). In MG, reported deaths were on  
136 average ~229 km (CI 95% 1.39-488) away from Belo Horizonte, while in SP they were ~28 km  
from São Paulo (CI 95% 0.05-270), and in RJ ~18 km away from Rio de Janeiro (CI 95% 1.45-  
138 142).

Typically, incidence (cases, deaths) would be normalized per 100K individuals, taking into account  
140 the total population size of each state. Because of the very different spatial dispersion of cases and  
deaths in MG when compared to SP and RJ, we decided to also calculate the effective population  
142 size - the sum of the population sizes of all municipalities with reports. When using reported cases,  
we found that the effective population sizes were ~100%, ~100% and 64% of the total population  
144 sizes of RJ, SP and MG, respectively. When using reported deaths, the effective population sizes  
were ~95%, ~92%, and 35% of the total population sizes of RJ, SP and MG, respectively. Overall  
146 these numbers suggest that in MG cases and deaths have been reported only in a subset of the  
overall population, while in the other states SARS-CoV-2 appears widely dispersed. Incidence of  
148 reported cases per 100K using the effective population size was ~60 in SP, ~51 in RJ and ~7.85 in  
MG (S7 Fig), while incidence of deaths per 100K was ~5.56 in SP, ~4.69 in RJ and ~0.94 in MG  
150 (S12 Fig).

In MG, samples from (clinically) suspected cases were screened at the Central Public Health  
152 Laboratory/Octávio Magalhães Institute (IOM) of the Ezequiel Dias Foundation (FUNED), which  
belongs to the public laboratories network of the Brazilian Ministry of Health (MoH). As of 3 April  
154 2020, IOM/FUNED had performed 3,303 RT-qPCR tests for SARS-CoV-2 on swab samples from

156 suspected cases. We used Nanopore sequencing to generate complete genomes from 40 COVID-19 patients living in 15 different MG's municipalities (Table 1).

158 **Table 1. Information on the 40 sequenced samples from Minas Gerais state.**

Project-ID	Lab ID	Sample type	Ct value	Onset date	Collection date	Age	Sex	State	Municipality	Travel information
CV1	47/20	SWAB	20.54	29/02/20	04/03/20	38	F	MG	Ipatinga	Israel
CV2	115/20	SWAB	24.41	06/03/20	08/03/20	44	F	MG	Sete Lagoas	Portugal, Spain
CV3	135/20	SWAB	27.77	08/03/20	09/03/20	45	M	MG	Belo Horizonte	Italy, Switzerland, Austria, Portugal
CV4	242/20	SWAB	21.92	N/A	09/03/20	65	M	MG	Juiz De Fora	USA
CV5	252/20	SWAB	29.93	12/03/20	12/03/20	32	M	MG	Belo Horizonte	-
CV6	298/20	SWAB	18.69	13/03/20	13/03/20	28	M	MG	Belo Horizonte	USA
CV7	352/20	SWAB	26.96	10/03/20	13/03/20	35	M	MG	Belo Horizonte	Switzerland, Portugal, England, Belgium, Spain
CV8	399/20	SWAB	22.61	06/03/20	13/03/20	34	M	MG	Belo Horizonte	-
CV9	428/20	SWAB	30.19	06/03/20	13/03/20	33	F	MG	Belo Horizonte	Sao Paulo (Brazil)
CV11	607/20	SWAB	27.92	10/03/20	16/03/20	40	F	MG	Mariana	Germany, Hungary, Czech Republic
CV12	615/20	SWAB	24.9	10/03/20	11/03/20	37	F	MG	Juiz De Fora	USA
CV13	660/20	SWAB	25.69	15/03/20	15/03/20	22	M	MG	Belo Horizonte	Italy
CV16	791/20	SWAB	20.64	15/03/20	16/03/20	52	M	MG	Belo Horizonte	-
CV17	809/20	SWAB	26.95	09/03/20	11/03/20	61	M	MG	Sete Lagoas	Portugal, Spain
CV18	833/20	SWAB	24.54	11/03/20	16/03/20	25	F	MG	Belo Horizonte	-
CV19	836/20	SWAB	22.04	11/03/20	16/03/20	22	M	MG	Belo Horizonte	Rio de Janeiro (Brazil)
CV20	838/20	SWAB	23.52	13/03/20	16/03/20	30	F	MG	Belo Horizonte	Colombia, Jamaica, Cayman Islands, Panama
CV21	842/20	SWAB	16.67	05/03/20	16/03/20	56	F	MG	Bom Despacho	-
CV22	895/20	SWAB	27.92	15/03/20	16/03/20	20	F	MG	Mariana	Germany
CV24	1028/20	SWAB	25.15	13/03/20	16/03/20	22	F	MG	Uberlândia	-
CV26	1078/20	SWAB	18.76	16/03/20	17/03/20	44	M	MG	Belo Horizonte	-
CV27	1166/20	SWAB	22.99	11/03/20	17/03/20	60	F	MG	Boa Esperança	-
CV28	1142/20	SWAB	22.21	13/03/20	17/03/20	46	F	MG	São João Del Rei	USA
CV31	1274/20	SWAB	17.38	16/03/20	17/03/20	35	M	MG	Betim	-
CV32	1290/20	SWAB	16.41	17/03/20	17/03/20	27	M	MG	Betim	-
CV33	1420/20	SWAB	18.79	14/03/20	17/03/20	35	M	MG	Sabara	-

CV34	1467/20	SWAB	22.31	16/03/20	18/03/20	48	F	MG	Belo Horizonte	-
CV35	1500/20	SWAB	24.06	07/03/20	18/03/20	75	M	MG	Poços De Caldas	Chile, Peru
CV36	1504/20	SWAB	24.07	18/03/20	18/03/20	50	F	MG	Muriae	-
CV40	1834/20	SWAB	23.97	18/03/20	19/03/20	29	M	MG	Belo Horizonte	-
CV41	1892/20	SWAB	22.84	16/03/20	18/03/20	20	F	MG	Serra Do Salitre	-
CV42	2119/20	SWAB	18.78	18/03/20	20/03/20	67	M	MG	São João Del Rei	-
CV43	2159/20	SWAB	24.81	14/03/20	17/03/20	19	F	MG	Patrocinio	-
CV44	2196/20	SWAB	23.47	17/03/20	18/03/20	19	F	MG	Patrocinio	-
CV45	2241/20	SWAB	22.85	14/03/20	20/03/20	58	M	MG	Muriae	Sao Paulo (Brazil)
CV46	2271/20	SWAB	22.9	19/03/20	20/03/20	35	M	MG	Belo Horizonte	-
CV47	2288/20	SWAB	22.4	17/03/20	19/03/20	35	M	MG	Belo Horizonte	-
CV48	2693/20	SWAB	22.43	19/03/20	20/03/20	74	M	MG	Varginha	-
CV49	2801/20	SWAB	20.95	16/03/20	22/03/20	30	M	MG	Belo Horizonte	-
CV50	5068/20	SWAB	31.86	20/03/20	26/03/20	44	M	MG	Mariana	-

Project-ID=sample identifier; Onset date= Symptoms onset date; F=Female; M=Male; MG=State of

160 Minas Gerais; N/A=Not Available.

162 Of the 40 samples, 17 (42.50%) were from the state's capital (Belo Horizonte), while the other  
 municipalities were represented by one, or a maximum of three samples. These samples were from  
 164 17 females and 23 males, with a collection date ranging from 4 March 2020, from the first positive  
 case diagnosed at IOM/FUNED, to 26 March 2020 (Table 1). The median age of the patients was 35  
 166 years (ranging from 19-79 years old). Selected samples had cycle threshold (Ct) values that ranged  
 from 16.41 to 31.86 (median= 22.945). We found no demographic variables (age, gender) to be  
 168 statistically correlated with sample Ct (S17 Fig). The new sequences have a median genome  
 coverage of 82.5% related to the reference genome NC\_045512.3 (S1 Table). All sequences  
 170 generated in this study have been submitted to the GISAID Initiative following the WHO guidelines  
 on the importance of sharing genomic data during situations of public health emergency of  
 172 international concern [25].

Of the 17 (42.5%, n=40) sequenced cases with available travel history information, 14 cases  
 174 (82.35%, n=17) reported international travel and three reported domestic travel. Two among the

later visited the city of São Paulo and one the city of Rio de Janeiro (Table 1). Of the international  
176 travel-related cases, seven (50%) were linked to travel to European countries (Portugal, Spain, Italy,  
Switzerland, Austria, England, Belgium, Germany, Czech Republic, and Hungary), while six  
178 reported travel to countries in the Americas (USA, Colombia, Jamaica, Cayman Islands, Panama,  
Chile, and Peru). One case reported travel to Israel.

180 To explore the history of the virus in MG, we performed a maximum likelihood (ML) phylogenetic  
analysis on the dataset containing the 40 new sequences plus other 3,062 sequences deposited in  
182 GISAID up to 15 April 2020. Our estimated ML phylogeny identified two major clades branching  
at the root of the tree (Fig 3). These two clades were named lineages A and B, following a SARS-  
184 CoV-2 lineage nomenclature recently proposed [26].

According to this nomenclature scheme, two main SARS-CoV-2 lineages could be identified as  
186 lineage A, defined by the Wuhan/WH04/2020 strain, and as lineage B represented by the Wuhan-  
Hu-1 strain. From these two main lineages, other sub-levels of descending lineages could be  
188 determined. Following the publication of this proposed lineage nomenclature scheme, a tool for  
automated lineage assignment was made publicly available in the GitHub repository  
190 (<https://github.com/hCoV-2019/pangolin>) [27]. We used this tool to perform the assignment of  
MG's sequences to the lineages [26]. The results of this lineage assignment showed that the majority  
192 (n=32, 80%) of MG sequences were assigned to lineage B.1. This also includes sequences from  
other countries such as Australia, China, Canada, Malaysia, and USA [28]. Moreover, two  
194 sequences were assigned to lineage B.2 (isolates CV22 and CV36), and one sequence to lineage A  
(isolate CV7) (see S2 Table for full results).

196 Slightly different from the lineage assignment approach mentioned before, in our ML phylogeny  
most of MG's new sequences (n=37, 92,5%) were placed in a descendant lineage we named B.1,  
198 which also included other sequences from GISAID sampled worldwide. Of these 37 sequences from  
MG within lineage B.1 (Fig 3), 11 are isolates from cases that reported travel to European countries

200 (isolates CV2, CV3, CV11, CV13, CV17) or the Americas (isolates CV4, CV6, CV12, CV20,  
CV28, CV35), in addition to the isolate CV1 from a traveler who returned from Israel. Two MG's  
202 sequences (CV22 and CV9) fell into lineage B, one of which (CV22) reported travel to Germany.  
The only sequence from MG that fell into lineage A refers to a case (CV7) that reported travel to  
204 European countries (Fig 3 and Table 1).

To assess these lineages in more detail and in time, we performed Bayesian time-measured  
206 phylogenetic analysis using a molecular clock model. We analyzed three sub-datasets (named subset  
A, subset B and subset B.1) extracted from each lineage from the ML tree that included Brazilian  
208 sequences. Our maximum clade credibility (MCC) trees showed that most of MG's sequences were  
interspersed with other isolates sampled from other countries (Fig 4b, c, d). This pattern, similar to  
210 that observed in other countries [28–30], is also in accordance with our ML tree and with the  
epidemiological data, indicating that these isolates were linked to travel exposure rather than  
212 community transmission, and reinforcing the idea that multiple independent introductions with  
source abroad have occurred in MG.

214 Despite the observed dispersed distribution, some sequences from MG grouped together, forming  
clusters that also included sequences from Brazil and other countries. Subset B.1 tree shows these  
216 clusters containing more than one sequence from MG (Fig 4d). However, these clusters have very  
low posterior probability support, because of the low genetic diversity of SARS-CoV-2 genomes  
218 currently available worldwide [31–33]. Nonetheless, four clusters, each consisting of only two MG  
sequences showed posterior probabilities of >80%. One of these clusters (Fig 4d), with a posterior  
220 probability of 100%, was formed by isolates CV34 and CV36, referring to cases of seemingly local  
transmission from contacts with a COVID-19 confirmed and suspected case, respectively.

222 From the time scaled phylogeny, we estimated the mean time of the most recent common ancestor  
(tMRCA) of the SARS-CoV-2 epidemic in Brazil to be 10 February 2020 (95% HPD interval 27  
224 January to 22 February 2020), which is consistent with the start of reported cases in Brazil and with

the epidemiological data from the first case confirmed in SP, regarding a traveler returning from  
226 Lombardy, Italy, on 21 February 2020 [11,13].

Despite the grouping of some MG sequences, we cannot infer a close relationship between these  
228 sequences with certainty at this stage, because of the small sample size data which covers only  
about 30 days of the epidemic in MG. That is, this dataset cannot fully represent the genetic  
230 diversity of SARS-CoV-2 strains circulating. Moreover, the low genetic diversity of sequences  
available so far limits conclusions about SARS-CoV-2 directionality and spread based solely on  
232 genetic data. As observed in another study [32], due to the described limitations of the available  
genomic data, the phylogenetic results presented should be approached with caution and considered  
234 as hypothesis-generating on the transmission events of SARS-CoV-2 in a local setting.

In conclusion, at the end of April 2020, the COVID-19 epidemic in the state of MG was still  
236 expanding ( $R>1$ ) and it is highly dispersed with cases and deaths reported mostly away from the  
capital city and with approximately only 64% and 35% of the total population being represented in  
238 case and death reported data, respectively. Genomic data and other epidemiological information  
from travel-related cases, allowed us to identify several introduction events that occurred  
240 independently in MG, further helping to explain the geographical patchiness of reported cases and  
deaths. These initial insights based on the restricted data that is available show that transmission is  
242 likely to continue in the near future and suggest room to improve reporting. Increasing COVID-19  
testing and SARS-CoV-2 genomic sequencing would help to better understand on how the virus is  
244 spreading and would thus inform better control of the COVID-19 epidemic in Brazil.

## 246 **Methods**

## 248 **Ethics statement**

Anonymized samples processed in this study were sent to the Central Public Health Laboratory/Octávio Magalhães Institute (IOM) of the Ezequiel Dias Foundation (FUNED), which belongs to public laboratories network from Brazilian Ministry of Health (BMoH). They were previously obtained by the local health services for routine diagnosis of SARS-CoV-2 and epidemiological surveillance. The availability of these samples for research purposes during outbreaks of international concern is allowed to the terms of the 510/2016 Resolution of the National Ethical Committee for Research – Brazilian Ministry of Health (CONEP - Comissão Nacional de Ética em Pesquisa, Ministério da Saúde), that authorize the use of clinical samples collected in the Brazilian Central Public Health Laboratories to accelerate knowledge building and contribute to surveillance and outbreak response.

260

## 262 **Sample collection and RT-qPCR diagnosis**

Samples used in this study were residual anonymized clinical samples, with no or minimal risk to patients, provided for research and surveillance purposes as described above. Swab samples collected from COVID-19 suspected cases were sent from throughout the state of MG to IOM-FUNED facilities. At IOM-FUNED, these samples were submitted to total RNA extraction with an automated protocol on the QIASymphony platform using QIASymphony DSP Virus/Pathogen Kit (Qiagen), following the manufacturer's recommendations. The molecular diagnosis was performed on a 7500 Real-Time PCR System (Thermofisher Scientific), using a RT-qPCR singleplex kit for the SARS-CoV-2 *envelope* and *RNA-dependent RNA polymerase* genes, developed by Bio-Manguinhos/Fiocruz (Rio de Janeiro, Brazil) and provided by the Brazilian Ministry of Health, following the manufacturer's recommendations. We selected 48 samples with RT-qPCR positive results available until 3 April 2020 from patients residing in different municipalities of the state of MG and presenting symptoms such as fever, cough, headache, dyspnea, sore throat and/or vomiting.

Samples were selected based on the Ct value  $\leq 32$ . Epidemiological data, such as symptoms, travel  
276 history and municipality of residency, was collected from medical records accompanying the  
collected samples provided by IOM/FUNED.

278

### **cDNA synthesis and sequencing multiplex PCR**

280 For the complementary DNA synthesis stage, the SuperScript IV Reverse Transcriptase kit  
(Invitrogen) was used following the manufacturer's instructions. The generated cDNA generated  
282 was subjected to sequencing multiplex PCR using Q5 High Fidelity Hot-Start DNA Polymerase  
(New England Biolabs) and a set of specific primers, designed by ARTIC Network  
284 ([https://github.com/artic-network/artic-ncov2019/tree/master/primer\\_schemes/nCoV-2019/V1](https://github.com/artic-network/artic-ncov2019/tree/master/primer_schemes/nCoV-2019/V1)) for  
sequencing the complete genome of SARS-CoV-2 [34]. PCR conditions have been previously  
286 reported in [34]. All experiments were performed on cabinet safety level 2.

### **Whole genome sequencing**

288 Amplified PCR products were purified using the 1x AMPure XP Beads (Beckman Coulter)  
following previously published protocol [35]. Purified PCR products were quantified using the  
290 Qubit® dsDNA HS Assay Kits (Invitrogen), following the manufacturer's instructions. Of the 48  
samples, only 40 contained enough DNA ( $\geq 2\text{ng}/\mu\text{L}$ ) to proceed to library preparation. Sequencing  
292 libraries were prepared using the Oxford Nanopore Ligation Sequencing Kit (SQK-LSK109)  
following previously published protocol [35]. Before pooling all samples, each sample was  
294 barcoded using the Native Barcoding Expansion kits (NBD104 and EXP-NBD114). After barcoding  
adaptor ligation, sequencing libraries were loaded on a flow cell (FLO-MIN106) for subsequent  
296 MinION sequencing, programmed to run for six hours. Reads were basecalled using Guppy and  
barcode demultiplexing was performed using qcat. Consensus sequences were generated by *de novo*  
298 assembling using Genome Detective and Coronavirus Typing Tool [36,37].

## 300 **Phylogenetic analysis**

Public SARS-CoV-2 complete genome sequences available up to 15 April 2020 were retrieved from  
302 the GISAID. Sequences were aligned using MAFFT (FF-NS-2 algorithm) following default  
parameters [38]. The alignment was manually curated to remove artifacts at the ends and within the  
304 alignment using Aliview [39]. Phylogenetic analysis of these genome sequences was performed  
using IQ-TREE (version 1.6.10) under the best fit model according to Bayesian Information  
306 Criterion (BIC) indicated by the Model Finder application implemented in IQ-TREE [40]. The  
statistical robustness of individual nodes was determined using 1000 bootstrap replicates.

308 Lineages assessment was conducted using Phylogenetic Assignment of Named Global Outbreak  
LINEages tool available at <https://github.com/hCoV-2019/pangolin> [27]. Four complete or near-  
310 complete SARS-CoV-2 genome datasets were generated. Dataset 1 ( $n = 3,102$ ) comprised the data  
reported in this study ( $n = 40$ ) plus publicly available SARS-CoV-2 sequences ( $n = 3,062$ ) from  
312 GISAID. Subsequently, to investigate the dynamic of the SARS-CoV-2 infection within the three  
different SARS-CoV-2 lineages (A, B and B.1), Bayesian molecular clock analysis was conducted  
314 on three smaller sub-datasets for each of the three lineages identified in the ML phylogeny and  
containing MG' isolates (dataset 2 *for* subset A  $n = 100$ ; dataset 3 *for* subset B  $n = 84$ ; dataset 4 *for*  
316 subset B.1  $n = 169$ ). ML trees from these three sub-datasets were inspected in TempEst v1.5.3 for  
presence of temporal signal [41]. Linear regression of root-to-tip genetic distance against sampling  
318 date indicated that the SARS-CoV-2 sequences evolve in clock-like manner ( $r = 0.43$ ;  $r = 0.47$ ;  $r =$   
 $0.40$  from subset A; B and B.1, respectively) (results in S18 Fig). For Bayesian time-scaled  
320 phylogenetic analysis we used BEAST 1.10.4 [42]. We employed the strict molecular clock model,  
which assumes a single rate across all phylogeny branches. We used the HKY+G4 codon  
322 partitioned (CP)1+2,3 substitution model and the exponential growth coalescent model [43]. We  
computed MCMC (Markov chain Monte Carlo) triplicate runs of 100 million states each, sampling  
324 every 10.000 steps for each sub-dataset. Convergence of MCMC chains was checked using Tracer

v.1.7.1 [44]. Maximum clade credibility trees were summarized from the MCMC samples using  
326 TreeAnnotator after discarding 10% as burn-in.

328

## **Epidemiological data assembly**

330 Data used in the epidemiological analysis were retrieved from <https://github.com/wcota/covid19br>  
[45].

332

## **Data Availability**

334 SARS-CoV-2 genome sequences generated in this study have been deposited in the GISAID  
platform (<https://www.gisaid.org/>), accession numbers IDs EPI\_ISL\_429664 to EPI\_ISL\_429703.

336

## **Acknowledgments**

338 We would like to thank all the authors who have kindly deposited and shared genome data on  
GISAID. A table with genome sequence acknowledgments can be found in S3 Table. We thank all  
340 personnel from Health Surveillance System from the state of MG that helped with epidemiological  
data collection. We are also grateful for the support provided by the personnel from the Central  
342 Public Health Laboratory/Octávio Magalhães Institute (IOM) of the Ezequiel Dias Foundation  
(FUNED).

344

## **Funding Statement**

346 This work was supported by the Pan American World Health Organization (PAHO) (VPGDI-003-  
FIO-19-2-2-30). MG is supported by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro  
348 (FAPERJ). V.F. and T.d.O. and V.F. are supported by the South African Medical Research Council

(MRC-RFA-UFSP-01-2013/UKZN HIVEPI) and the NIH H3AbioNet network, which is an  
350 initiative of the Human Health and Heredity in Africa Consortium (H3Africa). E.C.H. is supported  
by an Australian Research Council Australian Laureate Fellowship (FL170100022). J.L. is  
352 supported by a lectureship from the Department of Zoology, University of Oxford. J.X., V.F. and F.I  
is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil  
354 (CAPES) – Finance Code 001. F.I. is also supported by Fundação de Amparo à Pesquisa do Estado  
de Minas Gerais (FAPEMIG). A.S. has a scholarship from ZIKA - Announcement MCTIC/FNDCT-  
356 CNPq/MEC-CAPES/MS-Decit /No. 14/2016 - Prevention and Fight against Zika Virus. M.T.L. is  
supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ).The  
358 funders had no role in study design, data collection and analysis, decision to publish or preparation  
of the manuscript.

360

## Competing Interests

362 The authors have declared that no competing interests exist.

## 364 Author contributions

**Conceptualization:** LCJA, MG, JL, JX and MAAO; **Data Curation:** JX; MG; VF; TdO; JL; TO;  
366 EH; and LCJA; **Formal Analysis:** JX; MG; VF; TdO; and JL; **Investigation:** JX; MG; VF; TA;  
AVBC; AAR; FI; KNF; CGD; MVFS; CFSZ; TGSS; MTL; AF; AF; AMBF; MAMTS; VA; LCJA  
368 and MAAO; **Validation:** JX; MG; JL; TdO, LCJA and MAAO; **Writing – Original Draft**  
**Preparation:** JX; MG; JL; TO; LCJA and MAAO; **Writing – Review & Editing:** JX; MG; TA;  
370 JL; TdO, LCJA and MAAO.

372

## References

374

1. World Health Organization (WHO). Novel Coronavirus ( 2019-nCoV ) Situation Report - 1, 21 January 2020. WHO Bull. 2020.  
376
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395: 565–574. doi:10.1016/S0140-6736(20)30251-8  
378
3. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579: 265–269. doi:10.1038/s41586-020-2008-3  
380 382
4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382: 727–733. doi:10.1056/NEJMoa2001017  
384
5. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579: 270–273. doi:10.1038/s41586-020-2012-7  
386 388
6. Zhang T, Wu Q, Zhang Z. Pangolin homology associated with 2019-nCoV. bioRxiv. 2020. doi:10.1101/2020.02.19.950253  
390
7. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020. doi:10.1038/s41591-020-0820-9  
392
8. World Health Organization (WHO). Coronavirus disease (COVID-19) Situation Report–106, 5 May 2020. 2020. Available: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200505-covid-19-sitrep-106.pdf?sfvrsn=47090f63\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200505-covid-19-sitrep-106.pdf?sfvrsn=47090f63_2)  
394
9. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5: 536–544. doi:10.1038/s41564-020-0695-z  
396 398
10. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19). Situation Report – 51 11 March 2020. 2020. Available: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57\\_10](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10)  
400
11. Ministério da Saúde. Boletim Epidemiológico Especial-14 / SE 18-26 de abril de 2020 COE-COVID19. 2020. Available: <https://portalarquivos.saude.gov.br/images/pdf/2020/April/27/2020-04-27-18-05h-BEE14-Boletim-do-COE.pdf>  
402 404

- 406 12. World Health Organization (WHO). Coronavirus disease (COVID-19) Situation Report –  
103, 02 May 2020. 2020.
- 408 13. Jaqueline Goes de Jesus, Sacchi C, Claro I, Salles F, Manulli E, Silva D da, et al. First cases  
of coronavirus disease (COVID-19) in Brazil, South America (2 genomes, 3rd March 2020).  
410 In: *Virological: genome reports* [Internet]. 2020 p. 1. Available: [http://virological.org/t/first-](http://virological.org/t/first-cases-of-coronavirus-disease-covid-19-in-brazil-south-america-2-genomes-3rd-march-2020/409)  
412 [cases-of-coronavirus-disease-covid-19-in-brazil-south-america-2-genomes-3rd-march-](http://virological.org/t/first-cases-of-coronavirus-disease-covid-19-in-brazil-south-america-2-genomes-3rd-march-2020/409)  
2020/409
- 414 14. Instituto Brasileiro de Geografia e Estatística - IBGE. Cidades e Estados: Minas Gerais.  
2020. Available: <https://www.ibge.gov.br/cidades-e-estados/mg.html>
- 416 15. Gardy JL, Loman NJ. Towards a genomics-informed, real-time, global pathogen surveillance  
system. *Nature Reviews Genetics*. 2018. pp. 9–20. doi:10.1038/nrg.2017.88
- 418 16. Ministério da Saúde. Secretaria-Geral da Presidência da República - Imprensa Nacional:  
Portaria Nº 188, De 3 De Fevereiro De 2020. In: *Diário Oficial da União* [Internet].  
420 Available: [http://www.in.gov.br/en/web/dou/-/portaria-n-188-de-3-de-fevereiro-de-2020-](http://www.in.gov.br/en/web/dou/-/portaria-n-188-de-3-de-fevereiro-de-2020-241408388)  
241408388
- 422 17. Secretaria de Estado de Saúde de Minas Gerais. Boletim Epidemiológico COVID-19:  
Doença causada pelo coronavírus –19 28 de abril de 2020. 2020. Available:  
424 [https://saude.mg.gov.br/images/noticias\\_e\\_eventos/000\\_2020/mar\\_abr\\_maio/28.04.2020\\_Bo-](https://saude.mg.gov.br/images/noticias_e_eventos/000_2020/mar_abr_maio/28.04.2020_Boletim_epidemiologico_COVID-19_MG.pdf)  
letim\_epidemiologico\_COVID-19\_MG.pdf
- 426 18. Instituto Brasileiro de Geografia e Estatística - IBGE. Cidades e Estados - Belo Horizonte.  
2020. Available: <https://www.ibge.gov.br/cidades-e-estados/mg/belo-horizonte.html>
- 428 19. Spychalski P, Błażyńska-Spychalska A, Kobiela J. Estimating case fatality rates of COVID-  
19. *The Lancet. Infectious diseases*. 2020. doi:10.1016/S1473-3099(20)30246-2
- 430 20. Russell TW, Hellewell J, Jarvis CI, Zandvoort K Van, Abbott S, Ratnayake R, et al.  
Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using  
432 age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020.  
*Eurosurveillance*. 2020. doi:10.2807/1560-7917.ES.2020.25.12.2000256
- 434 21. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the  
severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis*. 2020.  
doi:10.1016/S1473-3099(20)30243-7
- 436 22. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating  
clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. *Nat Med*.  
438 2020. doi:10.1038/s41591-020-0822-7
- 440 23. Flaxman S, Mishra S, Gandy A, Unwin JT, Coupland H, Mellan TA, et al. Estimating the  
number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11  
European countries. *Imp Coll London*. 2020. doi:10.25561/77731
- 442 24. Wallinga J, Lipsitch M. How generation intervals shape the relationship between growth

- rates and reproductive numbers. *Proc R Soc B Biol Sci.* 2007. doi:10.1098/rspb.2006.3754
- 444 25. Moorthy V, Henao M, Preziosi M, Swaminathan S. Data sharing during the novel  
446 coronavirus public health emergency of international concern. *Bull World Health Organ.*  
2020; 4–6.
26. Rambaut A, Holmes EC, Hill V, O’Toole Á, McCrone J, Ruis C, et al. A dynamic  
448 nomenclature proposal for SARS-CoV-2 to assist genomic epidemiology. *bioRxiv.* 2020.  
doi:<https://doi.org/10.1101/2020.04.17.046086>
- 450 27. O’Toole Á, McCrone J. Phylogenetic Assignment of Named Global Outbreak LINEages.  
2020. Available: <https://github.com/hCoV-2019/pangolin>
- 452 28. Nextstrain. Genomic epidemiology of novel coronavirus - Global subsampling. 2020.  
Available:  
454 [https://nextstrain.org/ncov/global?branchLabel=clade&c=clade\\_membership&r=location&s=](https://nextstrain.org/ncov/global?branchLabel=clade&c=clade_membership&r=location&s=Canada/BC_64686/2020)  
[Canada/BC\\_64686/2020](https://nextstrain.org/ncov/global?branchLabel=clade&c=clade_membership&r=location&s=Canada/BC_64686/2020)
- 456 29. Munnink BBO, Nieuwenhuijse DF, Stein M, O’Toole Á, Haverkate M, Mollers M, et al.  
458 Rapid SARS-CoV-2 whole genome sequencing for informed public health decision making  
in the Netherlands. *bioRxiv.* 2020. doi:<https://doi.org/10.1101/2020.04.21.050633>
30. Lu J, Plessis L du, Liu Z, Hill V, Kang M, Lin H, et al. Genomic epidemiology of SARS-  
460 CoV-2 in Guangdong Province, China. *medRxiv.* 2020. doi:10.1101/2020.04.01.20047076
31. Mavian C, Marini S, Manes C, Capua I, Prospero M, Salemi M. Regaining perspective on  
462 SARS-CoV-2 molecular tracing and its implications. *medRxiv.* 2020.  
doi:10.1101/2020.03.16.20034470
- 464 32. Mavian C, Marini S, Prospero M, Salemi M. A snapshot of SARS-CoV-2 genome availability  
up to 30th March, 2020 and its implications. *bioRxiv.* 2020; 2020.04.01.020594.  
466 doi:10.1101/2020.04.01.020594
33. Rambaut A. Phylodynamic Analysis | 176 genomes | 6 Mar 2020. In: [virological.org](http://virological.org)  
468 [Internet]. 2020. Available: [http://virological.org/t/phylodynamic-analysis-176-genomes-6-](http://virological.org/t/phylodynamic-analysis-176-genomes-6-mar-2020/356)  
[mar-2020/356](http://virological.org/t/phylodynamic-analysis-176-genomes-6-mar-2020/356)
- 470 34. Quick J. nCoV-2019 sequencing protocol. [protocols.io](https://protocols.io); 2020.  
doi:[dx.doi.org/10.17504/protocols.io.bbmuk6w](https://doi.org/10.17504/protocols.io.bbmuk6w)
- 472 35. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, et al. Multiplex  
474 PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly  
from clinical samples. *Nat Protoc.* 2017. doi:10.1038/nprot.2017.066
36. Cleemput S, Dumon W, Fonseca V, Karim WA, Giovanetti M, Alcantara LC, et al. Genome  
476 Detective Coronavirus Typing Tool for rapid identification and characterization of novel  
coronavirus genomes. *Bioinformatics.* 2020. doi:10.1101/2020.01.31.928796
- 478 37. Vilsker M, Moosa Y, Nooij S, Fonseca V, Ghysens Y, Dumon K, et al. Genome Detective:

- 480 An automated system for virus identification from high-throughput sequencing data.  
Bioinformatics. 2019. doi:10.1093/bioinformatics/bty695
38. Katoh K, Rozewicki J, Yamada KD. MAFFT online service: Multiple sequence alignment,  
482 interactive sequence choice and visualization. *Brief Bioinform.* 2019;20: 1160–1166.  
doi:10.1093/bib/bbx108
- 484 39. Laarson A. AliView: a fast and lightweight alignment viewer and editor for large data sets.  
Bioinformatics. 2014. doi:10.1007/s13398-014-0173-7.2
- 486 40. Nguyen LT, Schmidt HA, Von Haeseler A, Minh BQ. IQ-TREE: A fast and effective  
stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol.* 2015.  
488 doi:10.1093/molbev/msu300
- 490 41. Rambaut A, Lam TT, Max Carvalho L, Pybus OG. Exploring the temporal structure of  
heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol.* 2016.  
doi:10.1093/ve/vew007
- 492 42. Suchard MA, Lemey P, Baele G, Ayres DL, Drummond AJ, Rambaut A. Bayesian  
phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus Evol.* 2018.  
494 doi:10.1093/ve/vey016
- 496 43. Griffiths RC, Tavaré S. Sampling theory for neutral alleles in a varying environment. *Philos  
Trans R Soc Lond B Biol Sci.* 1994. doi:10.1098/rstb.1994.0079
- 498 44. Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior summarization in  
Bayesian phylogenetics using Tracer 1.7. *Syst Biol.* 2018. doi:10.1093/sysbio/syy032
- 500 45. Costa W. Confirmed cases and deaths of COVID-19 in Brazil, at municipal (city) level.  
2020. doi:10.34740/kaggle/ds/576001

502

504

506

508

## Figure legends

510 **Figure 1. Timeline of key events following the confirmation of the first confirmed case of**  
**COVID-19 in Brazil.** Events below the line occurred in Minas Gerais (MG) state, while national  
512 events are presented above the line. Codes in parentheses refer to the identification code (CV#) of  
the isolates from cases described in this study.

514

**Figure 2. SARS-CoV-2 epidemic curve and spatial distribution of cases and deaths reported in**  
516 **the states of Minas Gerais (MG), São Paulo (SP) and Rio de Janeiro (RJ) .** Panel A: Daily  
confirmed cases of COVID-19 in the state of MG. The X axis represents the days from the first case  
518 in Brazil until 28 April 2020, while the Y axis represents the number of cases. The opposite side of  
the Y axis represents the number of deaths related to COVID-19. Numbers from Y axis are  
520 represented as  $\log_{10}$ . Panel B and C: Map with location (municipality) of deaths and case events,  
colored by total number of reports. Different background colors highlight the boundaries of the  
522 three states: Green for SP, purple for MG, Blue for RJ.

524 **Figure 3. Phylogenetic analysis of the SARS-CoV-2 isolated in the state of MG, Brazil.** A  
Maximum likelihood phylogeny inferred using 40 genome sequences from SARS-CoV-2 generated  
526 in this study and 3062 sequences already deposited in GISAID.


528 **Figure 4. Bayesian analysis of the SARS-CoV-2 isolated in the state of MG, Brazil.** (a) Map of  
the MG state showing the number of SARS-CoV-2 new sequences by patient's municipality. b)  
530 Molecular clock phylogeny of the subset from lineage A, including one new sequence from MG. c)  
Molecular clock phylogeny of the subset from lineage B, including two new sequences from MG.  
532 d) Molecular clock phylogeny of the subset from lineage B.1, including 37 new sequences from

MG. For molecular clock phylogenies, numbers along branches represent posterior probabilities and  
534 colors represent different sampling locations.


536

538

540




A




B

Spatial distribution of deaths



C

Spatial distribution of cases



# SARS-CoV-2 lineages

● genomes from this study

